Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

199 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Urine Pregnancy Test Prompt Week 24 Mepolizumab HES NCT00086658 - Urine Pregnancy Test Prompt Week 24

- 12-07-17 - 1 Formulier, 1 Itemgroep, 2 Data-elementen, 1 Taal
Itemgroep: Urine Pregnancy Test
Study part: Urine Pregnancy Test Prompt Week 24.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Central Laboratory –Blood Week 24 Mepolizumab HES NCT00086658 - Central Laboratory –Blood Week 24

- 12-07-17 - 1 Formulier, 1 Itemgroep, 2 Data-elementen, 1 Taal
Itemgroep: Central laboratory
Study part: Central Laboratory –Blood Week 24. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 24 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 24

- 12-07-17 - 1 Formulier, 1 Itemgroep, 5 Data-elementen, 1 Taal
Itemgroep: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 24.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 24 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 24

- 12-07-17 - 1 Formulier, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: Corticosteroid Medication
Study part: Corticosteroid Medication Week 24. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Vital Signs Pre- Infusion Week 24 Mepolizumab HES NCT00086658 - Vital Signs Pre- Infusion Week 24

- 12-07-17 - 1 Formulier, 1 Itemgroep, 8 Data-elementen, 1 Taal
Itemgroep: VITAL SIGNS
Study part: Vital Signs Pre- Infusion Week 24.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Concomitant Medications Week 24 Mepolizumab HES NCT00086658 - Concomitant Medications Week 24

- 12-07-17 - 1 Formulier, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: Concomitant Medications
Study part: Concomitant Medications Week 24. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Adverse Events Week 24 Mepolizumab HES NCT00086658 - Adverse Events Week 24

- 12-07-17 - 1 Formulier, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: Adverse Events
Study part: Adverse Events Week 24. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Investigational Product – IV Dosing Week 20 Mepolizumab HES NCT00086658 - Investigational Product – IV Dosing Week 20

- 12-07-17 - 1 Formulier, 1 Itemgroep, 6 Data-elementen, 1 Taal
Itemgroep: Investigational Product Dose Intravenous
Study part: Investigational Product – IV Dosing Week 20. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 20 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 20

- 12-07-17 - 1 Formulier, 1 Itemgroep, 5 Data-elementen, 1 Taal
Itemgroep: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 20.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

12-Lead ECG Week 20 Mepolizumab HES NCT00086658 - 12-Lead ECG Week 20

- 12-07-17 - 1 Formulier, 1 Itemgroep, 4 Data-elementen, 1 Taal
Itemgroep: 12-Lead ECG
Study part: 12-Lead ECG Week 20. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Urine Pregnancy Test Prompt Week 20 Mepolizumab HES NCT00086658 - Urine Pregnancy Test Prompt Week 20

- 12-07-17 - 1 Formulier, 1 Itemgroep, 2 Data-elementen, 1 Taal
Itemgroep: Urine Pregnancy Test
Study part: Urine Pregnancy Test Prompt Week 20. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Central Laboratory –Blood Week 20 Mepolizumab HES NCT00086658 - Central Laboratory –Blood Week 20

- 12-07-17 - 1 Formulier, 1 Itemgroep, 2 Data-elementen, 1 Taal
Itemgroep: Central laboratory
Study part: Central Laboratory –Blood Week 20. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial